Advertisement


Ramaswamy Govindan, MD: Roundup of Lung Cancer Findings

2015 IASLC World Conference on Lung Cancer

Advertisement

Ramaswamy Govindan, MD, of Washington University, summarizes three important papers: ROVA-T in relapsed and refractory small cell lung cancer, genomic characterization of large-cell neuroendocrine tumors, and the ECOG study on bevacizumab following chemotherapy for resected non–small cell lung cancer.



Related Videos

Lung Cancer

Tony Mok, MD, and Fred R. Hirsch, MD, PhD: Summary of the IASLC Presidential Symposium

Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).

Lung Cancer

Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).

Lung Cancer

Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk

Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).

Lung Cancer
Symptom Management

Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials

Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).

Lung Cancer

Everett E. Vokes, MD, on Controversies in Stage IIIA Disease

Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).

Advertisement

Advertisement




Advertisement